[1] Oakes K. Hepatitis B: prevalence and pathophysiology. Nursing Times, 2014, 110: 12-16.
[2] Lampertico P, Maini M, Papatheodoridis G. Optimal Management of Hepatitis B Virus Infection - EASL Special Conference. J Hepatol, 2015, 63: 1238-1253.
[3] Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology, 2010, 139: 474-482.
[4] European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012, 57: 167-185.
[5] 科技部十二五重大专项联合课题组专家. 乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理. 临床肝胆病杂志, 2014, 30: 99-108.
[6] Martin P, Lau DT, Nguyen MH, et al. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clin Gastroenterol Hepatol, 2015, 13: 2071-2087.
[7] Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut, 2012, 61 Suppl 1: i18-24.
[8] Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology, 2010, 51: 415-421.
[9] Pan X, Zhang K, Yang X, et al. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One, 2013, 8: e68568.
[10] Wang L, Liu F, Liu YD, et al. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat, 2010, 17: 298-304.
[11] He D, Guo S, Chen W, et al. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative. BMC Infect Dis, 2013, 13: 458.
[12] Song MJ, Song do S, Kim HY, et al. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol, 2012, 18: 6277-6283.
[13] Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management. J Hepatol, 2014, 61: 1407-1417.
[14] Chi H, Hansen BE, Yim C, et al. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther, 2015, 41: 867-876. |
